Artificial intelligence has facilitated discovery of Bufalin as a molecular glue degrader targeting estrogen receptor alpha (ERα), crucial in many hormone-driven cancers. Published in Nature Communications, this work exemplifies AI’s accelerating impact on drug discovery processes in oncology.